How to buy Nurix Therapeutics stock | $32.88

Nurix Therapeutics, Inc is a biotechnology business based in the US. Nurix Therapeutics shares (NRIX) are listed on the NASDAQ and all prices are listed in US Dollars. Nurix Therapeutics employs 122 staff and has a trailing 12-month revenue of around USD$13 million.

How to buy shares in Nurix Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Nurix Therapeutics. Find the stock by name or ticker symbol: NRIX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Nurix Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$32.88, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Nurix Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Nurix Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Nurix Therapeutics share price

Use our graph to track the performance of NRIX stocks over time.

Nurix Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-29.

Latest market close	USD$32.88
52-week range	USD$15.21 - USD$50.825
50-day moving average	USD$38.5626
200-day moving average	USD$29.5844
Wall St. target price	USD$40.4
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.8243

Buy Nurix Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Nurix Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Nurix Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nurix Therapeutics price performance over time

Historical closes compared with the close of $32.88 from 2020-12-31

1 week (2021-01-12)	-19.82%
1 month (2020-12-22)	-27.50%
3 months (2020-10-19)	23.89%
6 months (2020-07-18)	N/A

1 year (2020-01-18)	N/A
2 years (2019-01-18)	N/A
3 years (2018-01-18)	N/A
5 years (2016-01-18)	N/A

Nurix Therapeutics financials

Revenue TTM	USD$13 million
Gross profit TTM	USD$-13,910,000
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	-283.59%
Book value	N/A
Market capitalisation	USD$1.6 billion

TTM: trailing 12 months

Shorting Nurix Therapeutics shares

There are currently 863,379 Nurix Therapeutics shares held short by investors – that's known as Nurix Therapeutics's "short interest". This figure is 0.6% up from 858,482 last month.

There are a few different ways that this level of interest in shorting Nurix Therapeutics shares can be evaluated.

Nurix Therapeutics's "short interest ratio" (SIR)

Nurix Therapeutics's "short interest ratio" (SIR) is the quantity of Nurix Therapeutics shares currently shorted divided by the average quantity of Nurix Therapeutics shares traded daily (recently around 122291.64305949). Nurix Therapeutics's SIR currently stands at 7.06. In other words for every 100,000 Nurix Therapeutics shares traded daily on the market, roughly 7060 shares are currently held short.

However Nurix Therapeutics's short interest can also be evaluated against the total number of Nurix Therapeutics shares, or, against the total number of tradable Nurix Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nurix Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Nurix Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0339% of the tradable shares (for every 100,000 tradable Nurix Therapeutics shares, roughly 34 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nurix Therapeutics.

Find out more about how you can short Nurix Therapeutics stock.

Nurix Therapeutics share dividends

We're not expecting Nurix Therapeutics to pay a dividend over the next 12 months.

Nurix Therapeutics overview

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.

Frequently asked questions

• What percentage of Nurix Therapeutics is owned by insiders or institutions?

  Currently 9.409% of Nurix Therapeutics shares are held by insiders and 82.111% by institutions.

• How many people work for Nurix Therapeutics?

  Latest data suggests 122 work at Nurix Therapeutics.

• When does the fiscal year end for Nurix Therapeutics?

  Nurix Therapeutics's fiscal year ends in November.

• Where is Nurix Therapeutics based?

  Nurix Therapeutics's address is: 1700 Owens Street, San Francisco, CA, United States, 94158

• What is Nurix Therapeutics's ISIN number?

  Nurix Therapeutics's international securities identification number is: US67080M1036